Business ❯ Pharmaceuticals

Regeneron Pharmaceuticals

Eylea Securities Financial Performance Market Strategies

Regeneron Tops Q3 Forecasts on Dupixent Strength as Eylea HD Faces FDA Delay

The company set a new timeline for Eylea HD’s prefilled syringe following an FDA rebuff tied to a Catalent inspection.